Who is eligible to be prescribed Wegovy for weight management?

To be eligible for a Wegovy prescription, an individual must be an adult with a body mass index (BMI) of 30 or higher, which is classified as obesity. Alternatively, adults with a BMI of 27 or higher, classified as overweight, may also be eligible if they have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It is crucial to understand that Wegovy is intended as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone solution. The decision to prescribe is ultimately made by a healthcare professional following a comprehensive evaluation of the patient’s health profile, potential benefits, and risks.

Let’s break down the core eligibility criteria in more detail. The foundation is built upon Body Mass Index, a measure of body fat based on height and weight. While BMI has its limitations and doesn’t account for factors like muscle mass, it remains a standard clinical tool for initial assessment.

Primary Eligibility Pathways for Wegovy

For the second pathway, the term “weight-related comorbidity” is key. These are serious health conditions that are often worsened by excess weight and can, in turn, be improved with significant weight loss. Common qualifying conditions include:

• Hypertension (High Blood Pressure): Excess weight forces the heart to work harder to pump blood throughout the body.
• Type 2 Diabetes or Prediabetes: Adipose tissue, particularly around the abdomen, contributes to insulin resistance.
• Dyslipidemia (High Cholesterol/Triglycerides): Weight loss can help improve lipid profiles by lowering LDL (“bad”) cholesterol and triglycerides while raising HDL (“good”) cholesterol.
• Cardiovascular Disease: This includes a history of heart attack, stroke, or peripheral artery disease.
• Sleep Apnea: A condition where breathing repeatedly stops and starts during sleep, strongly associated with obesity.

It’s not just about hitting a number on the scale. A doctor will conduct a thorough assessment to determine if wegovy is an appropriate choice. This evaluation goes beyond BMI and looks at your overall health journey. They will consider your history of weight loss attempts. Typically, a prescription is considered for individuals who have tried conventional methods—such as structured diet and exercise programs—without achieving or maintaining clinically meaningful weight loss (usually defined as at least 5% of body weight). They will review your complete medical history to identify any conditions that might make Wegovy unsuitable. This includes a detailed review of all current medications to check for potential interactions. Furthermore, they will assess your psychological readiness and understanding that this is a long-term treatment commitment, requiring significant lifestyle changes alongside the medication.

Understanding how Wegovy works sheds light on why these specific eligibility criteria are in place. Wegovy’s active ingredient, semaglutide, mimics a hormone called GLP-1 (glucagon-like peptide-1). This hormone is naturally released after eating and performs several actions that aid in weight management. It signals the brain’s appetite centers, leading to reduced hunger and increased feelings of fullness (satiety), so you naturally consume fewer calories. It slows down the emptying of the stomach contents into the intestines, which also contributes to a prolonged feeling of fullness after meals. In addition to its weight management effects, it helps the pancreas release insulin more effectively in response to meals, which is particularly beneficial for those with type 2 diabetes. By addressing the biological drivers of hunger, Wegovy helps create the calorie deficit needed for weight loss in a way that can feel more manageable than willpower alone.

It is equally important to know who should *not* take Wegovy. There are specific contraindications where the risks outweigh the potential benefits. The most critical contraindication is a personal or family history of a specific type of thyroid cancer called medullary thyroid carcinoma (MTC). This is based on findings in rodent studies, and while the relevance to humans is not fully established, the risk is considered serious enough to warrant a strict prohibition. Another major contraindication is Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a genetic disorder that also increases the risk of MTC. Wegovy should not be used by individuals with a known serious allergy to semaglutide or any of the other ingredients in the formulation. Its safety has not been established in individuals with a history of pancreatitis, so doctors will typically avoid prescribing it in such cases. Furthermore, it is not approved for use during pregnancy or breastfeeding, and women of childbearing age are advised to use contraception while on the medication.

The journey with Wegovy is not a quick fix; it’s a gradual process that requires patience and medical supervision. The treatment starts with a low dose, which is gradually increased over several months to a maintenance dose. This “dose escalation” schedule is designed to help your body adjust to the medication and minimize gastrointestinal side effects, which are common, especially when first starting or increasing the dose. These can include nausea, vomiting, diarrhea, and constipation. A healthcare provider will monitor your progress closely, typically every four weeks initially, to assess your response to the medication, manage any side effects, and provide ongoing support for dietary and lifestyle modifications. The goal is sustainable weight loss, and regular follow-ups are crucial for long-term success.

When considering eligibility, the conversation often turns to cost and insurance coverage, which can be significant barriers. Wegovy is a specialty medication with a high list price. Coverage varies dramatically between insurance providers and specific plans. Many plans have strict prior authorization requirements, meaning your doctor must submit detailed documentation proving you meet the specific criteria before the insurance company will approve payment. Some plans may have “step therapy” protocols, requiring you to try and fail on other, often cheaper, weight management medications before they will cover Wegovy. It is essential to contact your insurance provider directly to understand your plan’s specific coverage, copay amounts, and requirements. The manufacturer also offers a savings card for eligible commercially insured patients, which can reduce out-of-pocket costs.

For those who are eligible and for whom the medication is appropriate, the clinical results can be significant. In large-scale clinical trials lasting over 68 weeks, participants taking Wegovy, in combination with lifestyle intervention, achieved an average weight loss of around 15% of their initial body weight. This level of weight loss is associated with substantial improvements in weight-related comorbidities. For example, participants often saw marked improvements in blood sugar control, blood pressure readings, and cholesterol levels, potentially reducing the need for other medications and lowering the long-term risk of cardiovascular events. This underscores the purpose of the eligibility criteria: to identify individuals for whom the health benefits of significant weight loss are likely to be greatest.